AN2 Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Selling, General & Admin	14.76	12.75	4.67	1.27
Research & Development	54.87	29.51	16.91	6.02
Other Operating Expenses	0	0	0.04	6.32
Operating Expenses	69.64	42.26	21.61	13.61
Operating Income	-69.64	-42.26	-21.61	-13.61
Other Expense / Income	-4.9	-1.31	-0.07	-0
Pretax Income	-64.73	-40.96	-21.54	-13.6
Net Income	-64.73	-40.96	-21.54	-13.6
Preferred Dividends	0	1.82	6.52	0.98
Net Income Common	-64.73	-42.78	-28.06	-14.58
Shares Outstanding (Basic)	24	15	3	3
Shares Outstanding (Diluted)	24	15	3	3
Shares Change	53.85%	481.46%	2.71%	-
EPS (Basic)	-2.74	-2.79	-10.64	-5.68
EPS (Diluted)	-2.74	-2.79	-10.64	-5.68
Free Cash Flow	-53.29	-33.46	-20.48	-5.36
Free Cash Flow Per Share	-2.26	-2.18	-7.76	-2.09
EBITDA	-64.68	-40.88	-21.54	-13.6
Depreciation & Amortization	0.05	0.08	0	0
EBIT	-64.73	-40.96	-21.54	-13.6

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).